Le Lézard
Classified in: Science and technology
Subject: Product/Service

MemryX Begins Customer Sampling of AI Accelerator Chip


MemryX Inc., a pioneering start-up that designs breakthrough silicon for artificial intelligence (AI) processing for edge devices, announced today it has begun customer sampling of its revolutionary MX3 AI Accelerator.

The MX3 was created to become the easiest-to-use and most efficient edge AI accelerator. MemryX customers can compile any trained AI model with just a single click. Within minutes, the developer will achieve optimized model performance with high utilization (>50%) and full accuracy using the MX3. This is the revolutionary change MemryX is introducing for edge AI, which saves months of software development time and speeds time to market.

The MX3 can be used to accelerate AI processing in nearly any edge computing system, whether the legacy or a new design. The MX3 directly connects to any applications processor, providing scalable AI for a wide variety of industries including automotive, Industry 4.0, robotics, IOT, smart vision systems, edge computing, and the metaverse.

"Reaching the milestone of customer sampling is gratifying, but what's even better is the feedback from initial customer experience with the MX3," said MemryX CEO Keith Kressin. "Customers are seeing first-hand how our solution is different from other AI accelerators."

MemryX was co-founded in February 2019 by CTO Dr. Wei Lu, electrical engineering and computer science professor at the University of Michigan. The radically new at-memory compute and dataflow architecture offers high performance with low latency and low power consumption. Even more importantly, the architecture was designed to give customers the ability to seamlessly scale performance, power, and latency according to their application requirements.

Hardware kits and SDKs are available to customers upon request. To order ? and for more information ? please contact MemryX Vice President of Product and Business Development Roger Peene at [email protected].

About MemryX Inc.

MemryX Inc. is a fabless semiconductor company that designs edge AI processing solutions powered by a proprietary compute-at-memory technology and data-flow architecture. By combining high performance and accuracy with low system power and a high-performance architecture, MemryX solutions can power AI needs for several industries, including transportation, IoT, and a wide range of industrial and consumer applications.

MemryX is backed by leading investors including HarbourVest, Arm IoT Fund, eLab Ventures, M Ventures, and Motus Ventures. MemryX has headquarters in Ann Arbor, Mich., with offices in Taipei and Hsinchu, Taiwan.


These press releases may also interest you

at 00:45
Claudio Bono, Managing Director for two independent Hotels in Silicon Valley, is thrilled to unveil a groundbreaking platform and an idea that will transform the landscape of the urgent unhoused crisis and social issues. Leveraging his extensive...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Side Protocol with the OKX Wallet. Side Protocol is a cross-chain middleware protocol designed to enable seamless communication and asset transfer between heterogeneous...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...

26 avr 2024
The report titled "Cognitive Security Market by Component (Services, Solutions), Security Type (Application, Cloud, Cybersecurity), Application, Deployment Mode, Enterprise Type, Vertical - Global Forecast 2024-2030" is now available on...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...



News published on and distributed by: